- VNRX Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
CORRESP Filing
VolitionRx Limited (VNRX) CORRESPCorrespondence with SEC
Filed: 4 Nov 21, 12:00am
VOLITIONRX LIMITED
13215 Bee Cave Parkway
Suite 125, Galleria Oaks B
Austin, Texas 78738
November 4, 2021
SUBMITTED VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Mr. Alan Campbell
| Re: | VolitionRx Limited Acceleration Request |
|
| Registration Statement on Form S-3 |
|
| File No. 333-259783 |
| Requested Date: November 8, 2021 |
| Requested Time: 5:00 P.M. Eastern Time |
Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended (the “Securities Act”), VolitionRx Limited, a Delaware corporation (the “Company”), hereby respectfully requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to declare the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above, or as soon thereafter as practicable.
Should the Commission have any questions regarding this acceleration request, please do not hesitate to contact Marc G. Alcser, an attorney with the Company’s outside legal counsel, Stradling Yocca Carlson & Rauth, P.C., via telephone at (949) 725-4136 or via email at malcser@stradlinglaw.com.
|
| Sincerely, |
|
|
|
|
|
|
| VOLITIONRX LIMITED |
|
/s/ Cameron Reynolds | |||
|
|
|
|
|
| Cameron Reynolds | |
President and Chief Executive Officer |
cc:
Stradling Yocca Carlson & Rauth, P.C.
Marc G. Alcser, Esq.